While chemotherapy, radiation, and surgery have been the traditional mainstays of cancer treatment, immunotherapy is rapidly emerging as the basis for many clinical protocols. The foundations of cancer immunotherapy include monoclonal antibodies, immune checkpoint inhibitors, and cell-based approaches. The panel will address a wide range of topics, including PD-1 blockade, T cells and natural killer cells as modulators, and omics analyses. Perspectives from engineering, pharmaceutical science, and statistics will be provided.

Moderator:

Panelists:

• Arup Chakraborty, Robert T. Haslam Professor, Chemical Engineering, Physics, & Chemistry; Institute for Medical Engineering & Science, MIT
• Xiaoping Bao, Assistant Professor, Purdue University Davidson School of Chemical Engineering
• Sandro Matosevic, Assistant Professor, Department of Industrial and Physical Pharmacy, Purdue University College of Pharmacy
• Seung-Oe Lim, Assistant Professor, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy
• Min Zhang, Professor, Department of Statistics, Purdue University College of Science

Biography

Arup K. Chakraborty’s career has been focused on work that brings together approaches from different disciplines to understand diverse phenomena and harness that knowledge toward practical ends. He is currently the Robert T. Haslam Professor of Chemical Engineering, and Professor of Physics, and Chemistry at MIT. He served as the founding Director of MIT’s Institute for Medical Engineering and Science from February 2012 to January 2018. He is also a founding steering committee member of the Ragon Institute of MIT, MGH, and Harvard, and an Associate Member of the Broad Institute of MIT & Harvard. After obtaining his PhD in chemical engineering and postdoctoral studies, he joined the faculty at the University of California at Berkeley in December 1988. He rose through the ranks, and ultimately served as the Warren and Katherine Schlinger Distinguished Professor and Chair of Chemical Engineering, Professor of Chemistry, and Professor of Biophysics at Berkeley. He was also Head of Theoretical and Computational Biology at Lawrence Berkeley National Laboratory. In September 2005, Chakraborty moved to MIT. After an early career in guiding the engineering of polymers and catalysts using quantum mechanical calculations, since 2000, Chakraborty’s work has largely focused on bringing together immunology and the physical and engineering sciences; more specifically, the intersection of statistical mechanics and immunology. His interests span T cell signaling, T cell development and repertoire, and a mechanistic understanding of HIV evolution, antibody evolution, and vaccine design. Since 2016, he has also been interested in the role of phase separation in gene regulation. Chakraborty’s work at the intersection of disciplines has been recognized by numerous honors, including the NIH Director’s Pioneer Award, the E.O. Lawrence Medal for Life Sciences from the US DOE, Guggenheim Fellowship, the Allan P. Colburn and Professional Progress awards from the AIChE, a Dreyfus Teacher-Scholar award, and a National Young investigator award. Chakraborty was elected a member of the National Academy of Sciences and the National Academy of Engineering for completely different bodies of work. He is also a member of the National Academy of Medicine, making him one of 21 individuals who are members of all three branches of the US National Academies. He is a Fellow of the American Academy of Arts & Sciences and the American Association for the Advancement of Science, and serves on the US Defense Science Board. Chakraborty has received four teaching awards at Berkeley and MIT.

Watch Panel